Physician

Mohammad Maher Al Sayyad, MD, FACP

According to 2025 Medicare claims, Mohammad Sayyad, MD, FACP (NPI: 1396732913) practices nephrology in the Abilene, TX market, with the plurality of this provider's patient population coming from Taylor, TX. This provider's primary affiliated billing organization is JAMES D WEBSTER MD & ASSOCIATES (NPI: 1760594600; TIN: 751486519) and primary practice location at 79601-2931. Sayyad is affiliated with the Caravan Health ACO 43 LLC (ACO ID: A4974), Main Street Rural Health Magnolia ACO LLC (ACO ID: A5400), and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Sayyad's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 507 traditional Medicare patients, billed 2,533 HCPCS/CPT codes, and received $300,552 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 1,192 prescription claims across 268 beneficiaries totaling $216,224 in drug costs, led by Velphoro (Sucroferric Oxyhydroxide). 2022 DME data shows 49 claims. Open Payments data shows 2 records totaling $160. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $495,440 to $300,552. Similarly, Part D prescription costs have moved from a higher plateau to a lower plateau, from $409,295 to $216,224. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	637	5,110	$495,440
2016	564	4,604	$446,072
2017	525	3,888	$402,093
2018	483	3,494	$347,735
2019	461	3,106	$309,801
2020	412	2,643	$282,731
2021	352	2,151	$265,395
2022	617	2,306	$330,440
2023	583	2,742	$365,490
2024	507	2,533	$300,552

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	270	3,022	$409,295
2016	264	2,845	$357,422
2017	252	2,825	$589,995
2018	235	2,375	$317,515
2019	253	2,199	$209,569
2020	249	2,148	$172,292
2021	237	1,949	$185,869
2022	287	1,625	$218,355
2023	273	1,486	$232,822
2024	268	1,192	$216,224

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	74	$2,937
2016	N/R	160	$14,876
2017	N/R	233	$16,587
2018	N/R	178	$12,356
2019	N/R	187	$4,091
2020	N/R	143	$9,205
2021	N/R	62	$5,426
2022	N/R	49	$1,037
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	62	432	$249
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	349	757	$113
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	113	570	$83
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	59	69	$74
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	120	552	$55

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Velphoro	Sucroferric Oxyhydroxide	24	840	$90,141
Auryxia	Ferric Citrate	27	1,290	$60,169
Sevelamer Carbonate	Sevelamer Carbonate	77	3,685	$14,515
Tradjenta	Linagliptin	11	570	$9,649
Calcium Acetate	Calcium Acetate	45	2,250	$3,260

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$160	CALLIDITAS THERAPEUTICS US INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mohammad Maher Al Sayyad, MD, FACP?

Tedicare shows public-source Medicare data for Mohammad Maher Al Sayyad, MD, FACP (NPI 1396732913), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mohammad Maher Al Sayyad, MD, FACP have ACO affiliation data?

Mohammad Maher Al Sayyad, MD, FACP is shown with ACO affiliation data for Caravan Health ACO 43 LLC (MSSP, ACO ID A4974), Main Street Rural Health Magnolia ACO LLC (MSSP, ACO ID A5400), and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Mohammad Maher Al Sayyad, MD, FACP?

Mohammad Maher Al Sayyad, MD, FACP is linked to JAMES D WEBSTER MD & ASSOCIATES (billing NPI 1760594600) in the available physician profile data.

Does Mohammad Maher Al Sayyad, MD, FACP have Open Payments data?

Mohammad Maher Al Sayyad, MD, FACP has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.